

Tarceva® (erlotinib) Enrollment Form For Blue Cross Blue Shield of Rhode Island Members

Fax Referral To: 800-323-2445 Phone: 866-278-6634

Phone: 8	00-4/8-0034	Date:	Needs	by Date (Pie	ase Specity): _		
Ship to: Patient	Office Other:			-			
PAT	IENT INFORMATION			PRESCRIBER IN	FORMATION		
(Complete the following or send patient demographic sheet)			Prescriber's Name:				
Patient Name:			State License #:		UPIN:		
Address:			DEA #:		NPI #:		
City, State, Zip:			Group or Hospital:				
Home Phone:			Address:				
Alternate Phone:			City, State Zip:				
SS #:			Phone:		Fax:		
Insurance ID:	ice ID:		Contact Person:				
Date of Birth:	f Birth: Gender:		Contact Phone:				
INSURAN	CE INFORMATION	(If available, please	copy and attach the front	and back of insuran	ce and prescription drug	card)	
Primary Insurance: Subscriber: Subscriber:		Subs	criber ID#:	Name of Insur	of Insurer: Blue Cross Blue Shield of RI		
Secondary Insurance:	ondary Insurance: Subscriber: Subscriber:		criber ID#:	Name of Insur	of Insurer:		
	STATEMENT (OF MEDICAL NE	ECESSITY for BCBS	of Rhode Island	Members		
Diagnosis (ICD-9 code): ☐ 162.9 Pulmonary Malignancy ☐ 157.5			denocarcinoma of Pancreas • Date of Diagnosis:				
	Other:						
APPROVAL CRITERIA:	: CHECK ALL BOXES TH	AT APPLY:	,				
NOTE: Any areas not fill	ed out are considered not a	pplicable to your patie	nt & MAY AFFECT THE	OUTCOME of this re	quest.		
·	nosed with Metastatic Non-Sr			es 🗌 No	•		
		_		_	ne? OR	٦ No	
	d despite treatment with anoth			aciitaxei, or genicitabi	ne? OR Tes		
	nosed with pancreatic cancer?		Yes No				
• Will the patient be using	Tarceva in combination with	Gemzar (gemcitabine)?	☐ Yes ☐ No				
& Biologics Compendium ^{TI}	endia, American Hospital For M Category of Evidence and C be requested if documentation	Consensus are considered	d during prior authorization r	rmation, National Con review if the drug is be	prehensive Cancer Network ing prescribed for a condition	NCCN), and Drug on not listed above.	
Medical Necessity (please	attach all supporting documer	ntation):					
product in the company of the company	anaen an sapporting accume						
**NOTE: Pharmacies car	n call and confirm that the i						
	_	PRESCRII	PTION INFORMATION	ON			
MEDICATION	STRENGTH		DIRECTIONS		QUANTITY	REFILLS	
Tarceva® (erlotinib)	□ 25 ···		OD	1.			
	25mg	L Take one tabl	et po QD on an empty s	вютасп.	30-day supply		
	☐ 100mg						
	☐ 150mg	Other:					
					<u> </u>		
					•		
PRODUCT SUBSTITUT	TON PERMITTED	(Da	nte) DISPENSE A	S WRITTEN		(Date)	
		(Du	,			(200)	